Novavax Inc. filings document formal disclosures for a Nasdaq-listed biotechnology company focused on vaccine products, Matrix-M adjuvant technology and partnership-driven development. Recent 8-K reports record operating results, preliminary financial information, licensing arrangements for Matrix-M, Nuvaxovid marketing-authorization transfers, and facility-related agreements.
Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and governance procedures. The filings also identify Novavax common stock, par value $0.01 per share, as listed on The Nasdaq Global Select Market under NVAX.
Novavax, Inc. reported a major regulatory milestone as the U.S. FDA approved its supplemental Biologics License Application for the Nuvaxovid™ 2025-2026 COVID-19 vaccine formula. The vaccine is approved for adults 65 years and older and for individuals 12 to 64 years of age who have at least one underlying condition that places them at high risk for severe COVID-19 outcomes. The FDA also extended the shelf life of this Nuvaxovid™ 2025-2026 formula from three months to six months, which may help distribution and inventory management.
As part of the approval, the FDA is requiring two postmarketing commitment studies: a Phase 3 open-label, single-arm study to evaluate safety and immunogenicity, and a Phase 4 observer-blind, placebo-controlled, randomized clinical trial to evaluate post-COVID vaccination syndrome. Novavax highlighted the usual risks and uncertainties associated with its forward-looking statements, including regulatory, manufacturing, and supply-chain challenges.
Novavax, Inc. entered into exchange and subscription agreements to issue $225.0 million of new 4.625% Convertible Senior Notes due 2031. About $175.3 million of these 2031 notes will be issued in exchange for approximately $148.7 million of its existing 5.00% Convertible Senior Notes due 2027, with the balance of about $49.7 million sold for cash in a private placement.
The 2031 notes pay 4.625% interest, mature on September 1, 2031, and are initially convertible at 89.7384 shares per $1,000 principal, an effective conversion price of about $11.14 per share, a 27.5% premium to the $8.74 share price on August 20, 2025. Full conversion of the 2031 notes at the initial rate would result in issuance of 20,191,140 shares of common stock.
After the exchange, about $26.5 million of 2027 notes will remain outstanding. Novavax expects gross proceeds of approximately $49.7 million from the cash subscription and plans to use the net proceeds for general corporate purposes.
Novavax (NVAX) Q2-25 10-Q highlights:
- Q2 revenue fell 42% YoY to $239.2 m as product sales dropped to $10.7 m; licensing/royalty income of $228.5 m (mainly Sanofi milestone).
- Expenses cut 46% YoY to $138.2 m, producing operating income $101.1 m and net income $106.5 m (vs $162.4 m LY).
- 1H-25 revenue surged 78% to $905.9 m, driven by recognition of $575.7 m Canada APA termination and $175 m FDA BLA milestone from Sanofi; 1H net income +$625.2 m vs $14.8 m LY.
- Cash & marketable securities $612.3 m (down $311 m YTD) after $313 m operating cash burn and $28 m Canada refund; working capital $530 m.
- Deferred revenue down to $513 m (-$609 m YTD) as APAs unwind; shareholders’ equity turned positive at $37.6 m from a $623.8 m deficit.
- Key events: FDA BLA approval for pre-filled syringe COVID-19 vaccine; $175 m milestone from Sanofi; amended Takeda license ($27 m recognized); Gavi settlement structure unchanged.
- Company asserts no going-concern risk for the next 12 months.
Outlook: Profitability presently supported by one-off licensing and settlement items; core product sales remain low and cash burn continues. Monitoring demand for updated COVID-19 vaccine, completion of Sanofi tech transfer, and utilization of remaining $0.6 b deferred revenue is critical.
Novavax director Richard J. Rodgers received new equity compensation grants on June 20, 2025, consisting of:
- 28,326 stock options with an exercise price of $6.42 per share, exercisable until June 20, 2035
- 18,884 Restricted Stock Units (RSUs) convertible into common stock
Both grants are scheduled to vest 100% on the first anniversary of the grant date (June 20, 2024), contingent on continued service as a board member. The stock options represent the right to purchase Novavax common stock, while each RSU represents the right to receive one share of common stock upon vesting. This compensation package aligns with standard director equity incentive practices under the company's Amended and Restated 2015 Stock Incentive Plan.
Novavax director David M. Mott reported two significant equity compensation grants on June 20, 2025:
- Received 28,326 stock options with an exercise price of $6.42, exercisable until June 20, 2035. These options will fully vest on June 20, 2025, contingent on continued board service.
- Granted 18,884 Restricted Stock Units (RSUs) that will fully vest on June 20, 2025, subject to continued board service. Each RSU represents the right to receive one share of common stock.
The equity grants are part of Novavax's Amended and Restated 2015 Stock Incentive Plan. The one-year cliff vesting structure for both awards suggests standard annual director compensation. The filing was signed by Mark J. Casey as attorney-in-fact on June 24, 2025.
Novavax director Rachel K. King reported new equity compensation grants on June 20, 2025, consisting of:
- Stock Options: Received 28,326 options to purchase common stock at $6.42 per share, exercisable until June 20, 2035. These options will fully vest on June 20, 2025, subject to continued board service.
- Restricted Stock Units (RSUs): Granted 18,884 RSUs that convert to common stock shares. The RSUs will fully vest on June 20, 2025, contingent on continued board service.
The equity grants were made under Novavax's Amended and Restated 2015 Stock Incentive Plan. The Form 4 was filed by Mark J. Casey as attorney-in-fact on June 24, 2025. This compensation package aligns the director's interests with shareholders through both appreciation-based options and full-value RSUs.
Novavax director Richard Douglas received new equity compensation grants on June 20, 2025, consisting of:
- 28,326 stock options with an exercise price of $6.42 per share, exercisable until June 20, 2035
- 18,884 restricted stock units (RSUs) representing the right to receive an equal number of common shares
Both grants will fully vest on the first anniversary of the grant date (June 20, 2024), subject to continued service on the Board of Directors. The stock options were granted under Novavax's Amended and Restated 2015 Stock Incentive Plan. This Form 4 filing represents standard board of director equity compensation and was reported by Mark J. Casey as attorney-in-fact on June 24, 2025.
Novavax director Gregg H. Alton received new equity compensation grants on June 20, 2025, as reported in this Form 4 filing. The awards consist of:
- Stock Options: 28,326 options to purchase common stock at an exercise price of $6.42, expiring June 20, 2035
- Restricted Stock Units (RSUs): 18,884 RSUs, each convertible into one share of common stock
Both grants will fully vest on the first anniversary of the grant date (June 20, 2024), contingent on Alton's continued service on Novavax's Board of Directors. The RSUs were granted under the company's Amended and Restated 2015 Stock Incentive Plan. This compensation structure aligns the director's interests with shareholders through both appreciation potential (options) and direct equity ownership (RSUs).
Novavax director Margaret G. McGlynn received new equity compensation grants on June 20, 2025, as reported in this Form 4 filing. The awards consist of:
- Stock Options: 28,326 options to purchase common stock at an exercise price of $6.42, expiring June 20, 2035
- Restricted Stock Units (RSUs): 18,884 RSUs, each convertible into one share of common stock
Both grants will fully vest on the first anniversary of the grant date (June 20, 2024), contingent on McGlynn's continued service on the Board of Directors. The options and RSUs were awarded under Novavax's Amended and Restated 2015 Stock Incentive Plan. This appears to be standard annual director compensation, providing both immediate value through RSUs and potential upside through stock options.